European and Canadian regulators are evaluating widely prescribed anti-hypertensive aliskiren amid concerns about its safety. Maker Novartis recently halted a major clinical study on aliskiren's wider use because of
high adverse reactions among users with type 2 diabetes and renal impairment, and the drug proved less effective
than placebo. Aliskiren is named Tekturna in the U.S. and Rasilez in the EU.

Related Summaries